Loading clinical trials...

Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease | Clinical Trials | Clareo Health

TERMINATEDPHASE2

Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease

3-Month, Single Site or Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety Tolerability and Potential Effects of the Dietary Supplement Anatabloc(R) in Subjects With Alzheimer's Disease

NCT01669876•Rock Creek Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

To explore whether dietary supplementation with a version of Anatabloc(R) exerts an effect on blood levels of amyloid beta (Aβ), or impacts global or functional measures of Alzheimer's Disease (AD) in subjects with mild to moderate AD.

Eligibility

Age

65 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•At least 65 years old.
•Have a diagnosis of probable AD or a concurrent diagnosis of probable AD and possible or probable vascular dementia.
•Score 16 or more on the Mini-Mental State Examination (MMSE).
•Otherwise stable medical history and general health.
•Weigh between 45 kg and 120 kg inclusive.

Exclusion Criteria

•Have contra-indications, allergy, or sensitivity to the study products or their components.
•Be currently taking any of the following medications: systemic (oral or injectable) glucocorticoids; interferon-alpha; anti-CD20 antibody (e.g., rituximab); or anti-CTLA-4 antibody (e.g., ipilimumab).
•Be a current smoker or smokeless tobacco user.

Locations (1)

Roskamp Institute

Sarasota, Florida, United States

Key Dates

Start Date

August 1, 2012

Primary Completion Date

December 1, 2014

Completion Date

February 1, 2015

Last Updated

April 30, 2015

Enrollment

ACTUAL participants

Conditions

Alzheimer Disease

Interventions

Anatabloc(R)

DIETARY_SUPPLEMENT

Placebo

DIETARY_SUPPLEMENT

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 30, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease

Inclusion Criteria

Exclusion Criteria

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Longitudinal Early-onset Alzheimer's Disease Study Protocol

A Study of AMDX-2011P in Participants With Alzheimer's Disease